| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $13.6M | — | +48.3% |
| SG&A Expense | $6.1M | — | +21.9% |
| Operating Income | -$19.6M | — | -39.0% |
| Net Income | -$17.8M | — | -49.3% |
| EPS (Basic) | -$0.31 | — | -6.9% |
| EPS (Diluted) | -$0.31 | — | -6.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $14.7M | -70.3% | -83.9% |
| Short-term Investments | $121.0M | +14.3% | +267.9% |
| Current Assets | $140.0M | -12.2% | +10.6% |
| Total Assets | $191.9M | -8.4% | +13.9% |
| Current Liabilities | $8.9M | -18.4% | +27.1% |
| Total Liabilities | $10.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$21.3M | — | -45.1% |
| Capital Expenditures | $44K | — | +0.0% |
| Investing Cash Flow | -$14.7M | — | +74.8% |
| Financing Cash Flow | $1.1M | — | -33.9% |
| Free Cash Flow | -$21.4M | — | -44.9% |
| +6.4% |
| Stockholders' Equity | $181.2M | -7.7% | +14.3% |